Veralox Therapeutics, a preclinical stage company focused on accelerating the development of first-in-class therapeutics for unmet medical needs, has raised a $5.4 million seed funding round.
Japan-based Sumitomo Dainippon Pharma is set to take ownership of the stakes held by Roivant Sciences across five biopharma companies (Vants) in a deal worth $3bn (£2.43bn).
X-Chem has announced today a drug discovery partnership with Maruho to discover lead compounds for novel and challenging targets with applications for human diseases.
Boehringer Ingelheim has signed a licensing, development and commercialisation deal worth more than $700m (£573.85m) with Indian pharma company Lupin for the latter’s MEK inhibitor compound LNP3794.
US biotech company Insilico Medicine has developed a new artificial intelligence (AI) system for drug discovery, known as GENTRL.
Vertex Pharmaceuticals has agreed to acquire US-based biotech company Semma Therapeutics for $950m (£784.66m) in an all-cash deal with an aim to develop curative cell-based treatments for type 1 diabetes.
HiFiBiO Therapeutics, a US biotherapeutics company, which has developed a single-cell analytics platform for extensive immune profiling, has completed a $67m (£54.86m) Series C financing round.
Immatics Biotechnologies and Celgene have signed a collaboration and option deal worth up to $1.59bn (£1.3bn) to develop novel adoptive cell therapies against multiple cancers.
OncoNano Medicine, Inc. today announced that it has been awarded $15.4m (£12.6m) from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance ONM-500, one of OncoNano’s innovative oncology product candidates.
Zogenix has agreed to acquire Modis Therapeutics, a California-based biopharma company focused on developing disease-modifying therapies for rare genetic diseases, in a cash-cum-stock deal worth over $400m (£325.72m).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.